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Abstract:  
Objetive: The aim of this study was to explore β2-adrenoceptor (ADRB2) haplotype 
associations with phenotypes and quantitative traits related to insulin resistance (IR) and the 
metabolic syndrome (MS) in a polycystic ovary syndrome (PCOS) population.  A 
secondary purpose was to assess the association between ADRB2 haplotype and PCOS. 
Design: Genetic polymorphism analysis. Cross sectional case-control association study. 
 
Setting: Medical University Hospital and research laboratory. 
Patients: 165 unrelated women with PCOS and 116 unrelated women without PCOS 
(control sample).  
Measurements: Clinical and biochemical measurements, and ADRB2 genotyping in 
PCOS patients and control subjects. 
Methods: ADRB2 haplotypes (comprising rs1042711, rs1801704, rs1042713 and 
rs1042714 in that order), genotyping and statistical analysis to evaluate associations with 
continuous variables and traits related to IR and MS in a PCOS population. Associations 
between ADRB2 haplotypes and PCOS were also assessed.   
Results: We observed an age-adjusted association between ADRB2 haplotype CCGG and 
lower insulin (p=0.018) and HOMA (p=0.008) in the PCOS sample. Interestingly, the 
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expected differences in surrogate measures of IR between cases and controls were not 
significant in CCGG/CCGG carriers. In the case-control study, genotype CCGG/CCGG 
was associated with a 14% decrease in PCOS risk (p=0.043), taking into account 
confounding variables.  
Conclusions: Haplotype I (CCGG) has a protective role for IR and MS in PCOS. 
 
Introduction:  
Polycystic ovary syndrome (PCOS) is recognised as the most common endocrine disorder 
in women of reproductive age (1,2,3). Insulin resistance in these patients may play an 
important role in the development of the syndrome where insulin has an influence on LH 
and steroidogenesis. Besides, many PCOS women are obese and develop a number of 
complications associated with obesity. Genetic variants which influence insulin response 
and/or obesity may be related to increased prevalence of PCOS.  
The pathophysiological mechanisms responsible for the development of obesity and insulin 
resistance (IR) in PCOS are multifactorial and abnormal regulation of adipocyte lipolysis 
might be a key component. Obesity is associated with an increase in basal lipolysis (4) but 
a decrease in catecholamine-stimulated lipolysis (5,6) where the beta-adrenergic receptor 
plays a major role (4). In PCOS, catecholamine-induced lipolysis is reduced in 
subcutaneous (sc) fat (7) but increased in visceral fat (8), resulting in an increase in lipid 
content in fat cells and excess of fatty acid delivery to the liver which could lead to 
hyperinsulinaemia, glucose intolerance, and dyslipidaemia (9,10).  Such lipolysis defects 
are identical to those observed in the metabolic syndrome (MS) so it could be a primary 
pathogenic mechanism for the development of the three disorders: obesity, PCOS and MS.  
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Insulin resistance and concomitant hyperinsulinaemia are common features in PCOS 
patients (50-70%)(11), and, together with obesity (12), are frequent pathogenetic factors in 
MS. Moreover, MS frequency is increased in PCOS women compared with age- and 
weight-matched controls (13,14) with an overall prevalence of 43-47% (15), especially in 
women with high insulin levels and BMI (16).  
An obesogenic lifestyle seems to be the main factor underpinning common variants of 
obesity and insulin resistance; however, the role of genetic predisposition in various 
conditions, including PCOS, is increasingly recognized (17,18). 
We studied the β2-adrenoceptor (ADRB2) owing to its dominant effect as lipolytic receptor 
in human white adipose tissue (19) and skeletal muscle (20). Recently Masuo et al (21) 
reviewed the close relationships between β2- and β3-adrenoceptor polymorphisms 
accompanying elevated sympathetic nervous activity, blood pressure elevation, weight 
gain, and insulin resistance. 
The aim of this study was to explore associations between ADRB2 haplotypes and 
phenotypes and quantitative metabolic traits related to obesity, lipid metabolism and IR in a 
PCOS population. A secondary purpose of the present study was to perform a cross 
sectional case-control association study between PCOS and ADRB2 haplotypes.  
 
Subjects and methods: 
- Subjects 
220 women with PCOS were recruited from outpatients attending the Endocrine Division 
of Hospital Durand, Buenos Aires (2006-2010). A sample of 165 unrelated women was 
selected for the molecular study according to the availability of metabolic and 
anthropometric parameters, informed consent and the absence of consanguinity. 
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PCOS was defined by 1) the presence of hyperandrogenaemia or clinical 
hyperandrogenism, 2) oligo-ovulation, and 3) the exclusion of other disorders, as 
described by the NIH 1990 criteria (22).  
Patients who had any of the following illnesses, conditions or requirement were excluded: 
Cushing’s syndrome, 21-hydroxylase deficiency, thyroid dysfunction, hepatic or 
haematological disease, diabetes, or hyperprolactinaemia. 
Controls were unrelated healthy females, without clinical components of PCOS or family 
history of PCOS (self reported), with normal weight, waist circumference <88cm, normal 
findings on medical examination and blood count, and not taking any medication. 
Volunteers were Argentinian of self-reported European ancestry, particularly from southern 
European countries (Spain and Italy), living in Buenos Aires metropolitan area, randomly 
recruited between April 2007 and April 2009.  
This work was carried out in accordance with the Declaration of Helsinki, and approved by 
the Hospital ethics committee. All subjects gave their written consent. 
 
-Clinical measurements 
Anthropometric measurements (height, weight and waist circumference) were determined 
by a standardized protocol in every subject. Waist circumference (WC) was measured to 
the nearest 0.1cm, with an inelastic fibreglass standard tape, in a horizontal plane, over the 
unclothed abdomen, at the narrowest point between the costal margin and iliac crest. 
Measurement was made at the end of a normal expiration. Systolic (SBP) and diastolic 
(DBP) blood pressures were recorded using a standard mercury sphygmomanometer after 
at least 10 min of rest.  
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Blood samples were drawn after a 12h overnight fast. Total cholesterol (TC), triglycerides 
(TG), and high-density lipoprotein cholesterol (HDL-C) were determined in serum by 
enzymatic methods using commercial kits (TG Triglycerides GPO-PAP, CHOL 
Cholesterol CHOD-PAP and Phosphotungstate Precipitant, Roche Diagnostics, Mannheim, 
Germany) in a Hitachi 727 autoanalyzer. Intra-assay coefficients of variation (CVs) for TG 
and TC were 1.3 and 1.1%, respectively. Inter-assay CVs were 2.4% and 1.5%, 
respectively. Fasting plasma glucose (FPG) was determined by a glucose-oxidase method 
(GLU Glucose GOD-PAP, Roche Diagnostics, Mannheim, Germany) in a Hitachi 727 
autoanalyzer. Intra- and inter-assay CVs were 0.9 and 1.8%, respectively. Fasting serum 
insulin (FI) was measured by radioimmunoassay (RIA) with a commercial kit (Human 
Insulin Specific RIA kit, Linco Research Inc., St. Louis, MO, USA) by using a gamma 
counter (DPC Gambyt CR, Los Angeles, USA), with a lower detection limit of 2 mU/L, 
intra- and inter-assay CVs being <1 and <7.43%, respectively and cross-reactivity less than 
0.2% for intact human proinsulin. Homeostasis Model Assessment (HOMA) was calculated 
with the following formula: basal glucose mmol/L x basal insulin mIU/L/22.5. 
 
-Phenotype assessment 
In Table 1 we showed significant differences in continuous variables between PCOS and 
control samples (BMI, WC, SBP, DBP, FG, TC, TG, HDL-C, TG/C-HDL, fasting insulin). 
Each subject was assessed for the presence of 1) MS using the AHA/NHLBI (American 
Heart Association/National Heart, Lung and Blood Institute) criteria (23) [any 3 or more of 
the following: WC ≥ 88 cm, fasting TG ≥  1.7mmol/L, SBP ≥ 130 mmHg, and/or DBP ≥  
85 mmHg, fasting HDL-C ≤ 1.03mmol/L, and FPG ≥  5.6mmol/L]; 2) obesity (BMI ≥ 30.0 
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kg/m
2
) (24);  3) abdominal obesity (waist circumference ≥ 88 cm), 4) hypertriglyceridaemia  
(HTG) (fasting TG ≥  1.7mmol/L), 5) hypertriglyceridaemic waist (HW)  (TG ≥ 1.7mmol/L 
+ WC ≥ 88cm); 6) decreased HDL-C (fasting HDL-C <1.03mmol/L); 7) impaired fasting 
glucose (IFG= Fasting plasma glucose ≥ 5.6mmol/L), 8) IR (insulin resistance) estimated 
by 75th percentile HOMA cutoff point (HOMA>2.3=IR). 
 
-Genotyping 
As described previously (25), we developed a simple method of genotyping ADBR2 
haplotypes composed of rs1042711, rs1801704, rs1042713 and rs1042714. The rs1042711 
(-47 C/T) and rs1801704 (-20 C/T) are located in the 5’ leader cistron and rs1042713 
(c.46A>G, Arg16Gly, R16E) and rs1042714 (c.79C>G, Gln27Glu, Q27E) in exon 1. It was 
possible to identify three major haplotypes (I, II and III) considering the different 
combinations of the four polymorphisms presented in the amplified fragment. 
Data from International Haplotype Map Project (http://hapmap.ncbi.nlm.nih.gov/) for 
European Americans from Utah (HapMap-CEU) and the software Haploview 4.1 (26) 
provided us tag-SNPs in LD; with a minor allele frequency (MAF) ≥0.10, minimum r2 
≥0.8, and minimum LOD =3.0. 
Briefly, genomic DNA was isolated from peripheral blood according to standard 
procedures. PCR was carried out to amplify a 353 bp region of ADBR2, single-strand 
conformation polymorphisms (SSCP) gel electrophoresis was performed and visualized 
with silver staining. The PCR-SSCP procedure was validated with automated sequencing. 
Genotyping accuracy was assessed by inclusion of duplicates and controls.  
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-Statistical analysis 
Analyses were done separately for haplotypes and followed up by analysis of individual 
SNPs. Quantitative data were expressed as means ± SE. For comparison of continuous 
variables we conducted one-way ANOVA with Levine's Test for equality of variances. 
Otherwise, we used Welch test. Regression analyses were used to adjust for possible 
confounding variables (age, BMI).  
The effects of a particular haplotype load (0= no copies, 1= 1 copy; and 2= 2 copies of the 
particular haplotype) on continuous or categorical variables were tested using linear or 
logistic regression respectively. 
Deviation of the genotype distribution from the Hardy–Weinberg Equilibrium (HWE) was 
tested using Chi square test for each SNP, for both samples.  
For individual SNP association analyses, we performed 1-df (1 degrees of freedom) test of 
association (dominant and recessive genetic models were tested).  
Differences between prevalence rates were assessed by Fisher exact test. 
We calculated odds ratio (OR) and 95% confidence intervals (95%CI) when appropriate. 
A p-value less than 0.05 was considered statistically significant. Statistical analyses were 
conducted using the program for Statistical Package for the Social Sciences, version 13.0 
for Windows (SPSS, Inc., Chicago, IL). 
 
Results 
The prevalence of MS and related traits in PCOS were as follows: MS (using AHA/NHLBI 
criteria) 20.2%; Obesity 42.1%; abdominal obesity 52.8%; HTG 25.0%; HW 19.6%; 
decreased HDL-C 21.9%; IFG 11.5%. Simultaneously the prevalences of IR defined by 
HOMA for lean and obese PCO patients respectively (34% and 70%) were determined.  In 
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Table 1 we showed the significant differences in continuous variables observed between 
PCOS and control samples (BMI, WC, SBP, DBP, FG, TC, TG, HDL-C, TG/C-HDL, 
fasting insulin). 
We identified the 3 main haplotypes that we previously observed in another Argentinian 
sample (25), which correlated with the haplotypes first described by Drysdale et al (27). 
The frequencies of the three haplotypes (rs1042711, rs1801704, rs1042713 and rs1042714 
in that order) were: CCGG (I) 0.31; TTAC (II) 0.38 and TTGC (III) 0.31. 
We identified the 6 genotypes CCGG/CCGG (I/I), CCGG/TTAC (I/II), CCGG/TTGC 
(I/III), TTAC/TTAC (II/II), TTAC/TTGC (II/III) and TTGC/TTGC (III/III).  
 
- ADRB2 haplotype frequency distributions according to phenotypes related to MS in 
PCOS 
We compared the overall frequency differences (3x2 contingency table) across the three 
possible haplotypes and the different phenotypes, and observed a borderline association 
between haplotype I (CCGG) and MS (p = 0.051; OR = 0.41, 95 % CI = 0.17 - 1.01). We 
could not find any significant association with obesity, abdominal obesity, IFG, HTG, 
decreased HDL-C, HW or IR phenotypes.  
To further explore the effect of the haplotype I load (0= no copies, 1= 1 copy; and 2= 2 
copies of the particular haplotype) we performed logistic regression analysis. We found a 
statistically significant association between haplotype I and MS (p = 0.042; OR= 0.37 (95 
% CI = 0.14 - 0.97) but differences were no longer significant after taking into account age 
(p = 0.077). No other significant associations were found between haplotype load and 
phenotypes under study in the PCOS sample.  
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Haplotype I was less represented in the PCOS IR-subgroup (HOMA>2.3) (haplotype I 
frequencies in IR and non IR women were 0.27 and 0.37, respectively) and we observed an 
association with insulin resistance taking into account age (p=0.083 and adjusted-p=0.033). 
Although haplotype I was less represented in the PCOS obese-subgroup (haplotype I 
frequency in obese and non obese individuals were 0.18 and 0.35, respectively) we did not 
observed any association with obesity (p=0.086 and p= 0.229 when age adjusted).  
 
- Haplotype load - association analysis of quantitative metabolic traits in PCOS 
 
The effects of haplotype I load on quantitative metabolic traits are represented in Figure 2. 
In PCOS, the correlation between decreased values of BMI, insulin, HOMA, TG/HDL-C, 
WC and BMI, and increase in haplotype I (X/X, I/X and I/I) load are shown.  
We performed linear regression analysis to assess the effects of a particular haplotype load 
on quantitative metabolic traits. We found an association of haplotype I load (CCGG) with 
BMI (p = 0.040), insulin (p = 0.015) and HOMA (p = 0.017). Differences in insulin and 
HOMA remained significant taking into account age (p=0.018 and p=0.008, respectively) 
and after adjusting for age and BMI (p=0.032 and p=0.014, respectively). 
We did not find any other significant regression association between haplotype I and lipid 
and/or other obesity-related variables in PCOS patients (waist circumference, triglycerides 
and TG/HDL-c). Data not shown. 
No significant association of haplotypes II (TTAC) or III (TTGC) with continuous 
variables was apparent. 
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Case – control association study between ADRB2 haplotypes and PCOS 
We did not find any evidence of association when comparing overall frequency differences 
across the three possible haplotypes between cases (PCOS) and controls (p=0.084, Figure 
1).  
 
We performed logistic regression analysis to assess the association between haplotype I 
load and presence of PCOS. We included in the model the variables previously associated 
with haplotype I in the PCOS sample (fasting insulin, HOMA-IR and MS) and age. 
Association of haplotype I with PCOS was significant under a recessive model (I/I vs. I/X 
+ X/X) (p = 0.043; OR = 0.14, 95 % CI = 0.02 - 0.93). 
The same study was performed with non insulin resistant PCOS (HOMA<2.3 by 75th 
percentile HOMA value) compared to the control group (non insulin resistant) and we 
observed a significant association of haplotype I with PCOS under a recessive model (I/I 
vs. I/X + X/X) (p = 0.004; OR = 0.026, 95 % CI = 0.002 - 0.32).  
Taking into consideration the intra PCOS association study performed previously, we 
analyzed the contribution of haplotype I load to quantitative traits related to obesity, lipid 
metabolism and surrogate measures of IR, between cases (PCOS) and controls. Figure 2 
shows that the PCOS genotype X/X carriers’ subgroup (without haplotype I) had 
significantly higher surrogate measures of IR (insulin, HOMA, TG and TG/HDL-C ratio) 
than controls (p < 0.005 adjusted by age and BMI). The genotype I/X individuals showed 
the same results but, interestingly, in the I/I genotype carriers’ subgroup, differences 
between cases and controls were not significant. The same results were observed when 
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analysis was performed between non IR PCOS and non obese PCOS vs. controls (non IR 
and non obese, respectively), data not shown. 
WC and BMI were compared, and statistically significant differences were observed 
between cases and controls, independently of haplotype I presence (p < 0.005 adjusted by 
age and BMI, Figure 2).  
 
- Single Locus Analysis 
We only performed single locus analysis of rs1042713 and rs1042714. rs1042711 in our 
sample seemed to be linked to rs1801704 and rs1042714 since we only found three 
haplotypes (CCGG, TTAC and TTGC, I, II and III respectively). Also, considering the 
linkage disequilibrium (LD) analysis with HapMap-CEU data, we observed that rs1042714 
was in linkage disequilibrium (LD) with rs1801704 (r
2
= 0.96) (Figure 3).  
 
Allelic frequencies were as follow: in the control sample: rs1042713 G 0.59 and A 0.41; 
rs1042714 C 0.68 and G 0.32; and in the PCOS sample: rs1042713 G 0.62 and A 0.38; 
rs1042714 C 0.69 and G 0.31. Both SNPs were in concordance with HWE as follows: 
rs1042713: Controls χ2 = 0.04, p = NS; PCOS χ2 = 0.17, p = NS; rs1042714: Controls χ2 = 
1.17, p = NS; PCOS χ2 = 0.31, p = NS. 
We did not find significant associations of rs1042713 with categorical or continuous 
variables in the PCOS sample. rs1042714 was not associated with phenotypes (categorical 
variables) under study in the PCOS sample but rs1042714 GG carriers showed lower 
fasting insulin (p = 0.022) and HOMA (p = 0.030) compared with allele C carriers 
(recessive model). Differences in insulin and HOMA remained significant after taking into 
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account age (p = 0.021 and p = 0.010, respectively) and after adjusting for age and BMI (p 
= 0.035 and p = 0.017, respectively) in the PCOS sample. 
rs1042713 and rs1042714 allele and genotype frequencies did not differ significantly 
between PCOS cases and control subjects. 
 
Discussion 
This is the first report that explores ADRB2 haplotypes (rs1042711, rs1801704, rs1042713 
and rs1042714) for their association with phenotypes and quantitative metabolic traits 
related to IR, obesity and lipid metabolism, in a Caucasian PCOS population. Beta 
adrenergic receptor activity was recently identified in the molecular ontology genes within 
the protein network constructed by Mohamed-Hussein and Harun, demonstrating a 
probable role of the gene in the pathophysiology of PCOS (28).  
We observed an association between ADRB2 haplotype CCGG (I) and absence of MS 
(significant) or insulin resistance (borderline) in PCOS women; results were confirmed by 
haplotype I load logistic regression. Although haplotype I was less represented in the PCOS 
obese-subgroup we did not observe any association with obesity. Furthermore, no 
associations with abdominal obesity, IFG, HTG, decreased HDL-C, HW or IR phenotypes 
were found.  
In PCOS patients, decreased values of BMI, insulin, HOMA, TG/HDL-C, WC and BMI 
correlated with increased haplotype I load (X/X, I/X and I/I). Particularly, we observed 
linear regression association of haplotype I load (CCGG) with lower insulin and HOMA.   
A case–control association study between ADRB2 haplotypes and PCOS was also 
performed, and we observed that CCGG/CCGG carriers had significantly lower risk of 
developing PCOS taking into account fasting insulin, HOMA-IR, MS and age. Genotype 
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CCGG/CCGG was associated with a 14% decrease in PCOS risk taking into account these 
confounding variables. This may therefore indicate that women who shared one or more of 
the confounding parameters analyzed, like fasting insulin, HOMA-IR, MS and the same 
age, would have a lower risk of developing PCOS if they carried two copies of haplotype 
CCGG. Interestingly, cases and controls within the CCGG/CCGG-carrier group had no 
significant differences in surrogate measures of IR (insulin, HOMA and TG/HDL-C ratio).  
In our previous study in another Argentine population (25), we found statistically 
significant frequency differences for haplotype CCGG/CCGG between obese and normal 
weight subjects (p: 0.0348, odds ratio: 0.2487, CI 95%: 0.07-0.91) indicating a possible 
protective role of the haplotype CCGG/CCGG for obesity. In the PCOS sample studied in 
this work, although haplotype CCGG was less represented in obese PCOS women, no 
significant differences attributable to the ADRB2 haplotypes were observed for WC and 
BMI.  
Taking all the results together, haplotype CCGG appears to have a protective role for IR, 
and MS in PCOS, regardless of age. Although the present study provides exploratory 
results and should be confirmed in a second and independent replication cohort, previous 
association studies have shown conflicting results regarding ADRB2 haplotypes and 
different phenotypes, as recently analyzed in a meta-analysis (29). Ethnic influences and 
differences in the degree of the phenotypes among research subjects would explain such 
discordances (30). 
The vast majority of association studies which have considered ADRB2 as a candidate gene 
have analyzed one or both of the non-synonymous coding polymorphisms (rs1042713, 
Arg16Gly and rs1042714, Gln27Glu) in different diseases. In an attempt to explore the 
association signal, we performed analysis with individual SNPs.  rs1042714 GG 
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(Glu27/Glu27) genotype carriers showed lower fasting insulin and HOMA compared with 
allele rs1042714C carriers (Gln27/Glu27 or Gln27/ Gln27) even after adjusting for age and 
BMI in the PCOS sample. Kurabayashi et al (31) reported that women with rs1042713AA 
(not GG, Arg16/Arg16) genotype or with either rs1042714CG (Gln27/Glu27) or GG 
(Glu27/Glu27) genotype had significantly higher insulin resistance than those with the 
rs1042713GG (Gly16/ Gly16) and rs1042714CC (Gln27/ Gln27) genotypes, in a Japanese 
PCOS sample.  
We did not find allelic association with PCOS in the sample studied. In the previous case-
control study, conducted by Kurabayashi et al. (31) (fifty-nine women with PCOS and 97 
controls), the rs1042714G allele frequency was shown to be significantly higher in PCOS 
patients when compared to controls, while the rs1042713G allele frequency was only 
slightly lower in the PCOS group as compared to controls. In contrast, we observed that the 
rs1042713 G allele frequency was only slightly higher in the PCOS group as compared to 
controls (0.62 vs. 0.59) and no differences were observed for the rs1042714 G allele (0.32 
vs. 0.31).  Contradictory results are probably due to the different allele frequencies 
observed (HapMap-JPT/CEU allele distribution, http://hapmap.ncbi.nlm.nih.gov/) or 
different LD structure in both populations. Furthermore, discrepancies in results have been 
reviewed by Masuo (6) in relation to ADRB2 polymorphisms and obesity, glucose 
intolerance, hypertension and/or diabetes. It must be considered that SNPs may be acting 
together in specific haplotype pairs (32) although each may have a different modest effect 
(32, 33, 34, 35) and might address these inconsistencies. 
Of note, a gene-wide association study (GWAS) of the ADRB2 candidate region, by means 
of the haplotype tagging strategy, would require genotyping rs1042713, rs1042714, 
rs1042718 and rs1042719, to capture 100% of alleles with minor allele frequency ≥ 0.10 
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(Figure 3). However, tagging only common SNPs, as we have done, excluded the 
possibility of discovering any substantial effect associated with low frequency SNPs.  
In conclusion, a protective role of haplotype I in insulin resistance would influence the 
development of PCOS, and other related metabolic disorders such as MS. Considering the 
complexity and heterogeneity of PCOS (32), and the possible pathogenetic role of the 
ADRB2 gene, ADRB2 haplotype genotyping in the early stages of PCOS could help to 
provide a risk predisposition assessment for IR and MS.  
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Table 1. Clinical characteristics 
Measure  Control women PCOS women P 
 
P
a
 
n 121 165   
Age 30.,78 ± 0.78 26.,42 ± 0.50 0.001 NA 
BMI (kg/m
2
) 21.08 ± 0.18 29.28 ± 0.63 0.001 0.001 
WC (cm) 71.05 ± 0.68 89.32 ± 1.61 0.001 0.001 
SBP (mmHg) 109.73 ± 2.33 111.23 ± 1.78 NS NS 
DBP (mmHg) 72.75 ± 0.91 72.22 ± 1.38 NS NS 
FG (mmol/L) 4.5080.92 ± 0.074 5.0791.39 ± 2.630.15 0.001 0.001 
T-C (mmol/L) 4.25164.31 ± 
3.150.08 
188.794.88 ± 
3.460.09 
0.001 0.001 
TG (mmol/L) 67.000.76 ± 2.890.03 123.591.40 ± 
7.120.08 
0.001 0.001 
HDL-C (mmol/L) 56.781.47 ± 1.430.04 51.321.33 ± 1.470.04 0.010 0.025 
TG/HDL-C 1.22 ± 0.06 2.,80 ± 0.24 0.001 0.001 
Fasting Insulin 
(mIU/L) 
5.65 ± 0.27 14.27 ± 0.86 0.001 0.001 
HOMA 1.09 ± 0.05 3.23 ± 0.22 0.001 0.001 
 
A
cc
ep
te
d 
A
rt
ic
le
 
© 2012 Blackwell Publishing Ltd 
 
A
cc
ep
te
d 
A
rt
ic
le
 
© 2012 Blackwell Publishing Ltd 
 
A
cc
ep
te
d 
A
rt
ic
le
 
© 2012 Blackwell Publishing Ltd 
 
